Abstract
Melanoma is a common aggressive skin cancer. Its numerous genetic mutations have become rich targets for systemic therapy with chemotherapy or immunotherapy. Surgery is the best initial treatment. Completion nodal dissection for sentinel node positive patients decrease regional occurrence but no survival benefit was found in a few studies. Radiotherapy (RT) is used as primary, adjuvant and palliative treatment. Specific scenarios with unknown primary, head and neck melanomas, and distant metastases are discussed. Systemic therapy includes molecular therapy based on diver mutation or immunotherapy. Treatment guidelines should be utilized by the multidisciplinary team to aid treatment decision making. Future improvement in outcome can only be achieved by enrollment of patient into clinical trials and therefore should be encouraged. Future research will be along the line of immunotherapy, target therapy, hyperthermia, nanoparticles, neutron, and radioisotope treatments.
Keywords: Sentinel node biopsy, systemic therapy, chemotherapy, radiotherapy, node dissection, targeted therapy, treatment, sites.
Current Cancer Therapy Reviews
Title:Melanoma
Volume: 12 Issue: 3
Author(s): Vamsee Torri, Wojciech Dolata, Khanh Vu, Arbind Dubey, Bryan Brunet and Patricia Tai
Affiliation:
Keywords: Sentinel node biopsy, systemic therapy, chemotherapy, radiotherapy, node dissection, targeted therapy, treatment, sites.
Abstract: Melanoma is a common aggressive skin cancer. Its numerous genetic mutations have become rich targets for systemic therapy with chemotherapy or immunotherapy. Surgery is the best initial treatment. Completion nodal dissection for sentinel node positive patients decrease regional occurrence but no survival benefit was found in a few studies. Radiotherapy (RT) is used as primary, adjuvant and palliative treatment. Specific scenarios with unknown primary, head and neck melanomas, and distant metastases are discussed. Systemic therapy includes molecular therapy based on diver mutation or immunotherapy. Treatment guidelines should be utilized by the multidisciplinary team to aid treatment decision making. Future improvement in outcome can only be achieved by enrollment of patient into clinical trials and therefore should be encouraged. Future research will be along the line of immunotherapy, target therapy, hyperthermia, nanoparticles, neutron, and radioisotope treatments.
Export Options
About this article
Cite this article as:
Torri Vamsee, Dolata Wojciech, Vu Khanh, Dubey Arbind, Brunet Bryan and Tai Patricia, Melanoma, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573394713666170113115759
DOI https://dx.doi.org/10.2174/1573394713666170113115759 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin
Current Pharmaceutical Design A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Radiopharmaceuticals to In Vivo Characterize Adrenal Incidentalomas:The Integrated Role of Radionuclide and Radiological Techniques
Current Radiopharmaceuticals Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Evaluation of Drug Targeting Strategies and Liposomal Trafficking
Current Pharmaceutical Design Quinone Methides and Their Biopolymer Conjugates as Reversible DNA Alkylating Agents
Current Organic Chemistry Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Functional Biomolecule Delivery Systems and Bioengineering in Cartilage Regeneration
Current Pharmaceutical Biotechnology Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy Bioequivalence and Pharmacogenetics
Current Pharmacogenomics and Personalized Medicine Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals Interaction of Oligomeric Breast Cancer Resistant Protein (BCRP) with Adjudin: A Male Contraceptive with Anti-Cancer Activity
Current Molecular Pharmacology Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response
Current Pharmaceutical Design Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design